1.87 USD
▲-0.03+8.72%
盘后 1.73 +0.58%
2026-08-03
市值
$79.55M
市盈率
—
EPS
-1.77
股息率
—
52 周区间
1.54 – 5.50
成交量
808.96K
Beta
1.19
目标价
11.00
52W 低 1.5452W 高 5.50
价格走势
公司简介
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease an...